Faculty Opinions recommendation of Definition of estrogen receptor pathway critical for estrogen positive feedback to gonadotropin-releasing hormone neurons and fertility.

2007 ◽  
Author(s):  
Andrea Gore
Keyword(s):  
Estrogen Receptor ◽  
Positive Feedback ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Estrogen Receptor Pathway ◽  
Definition Of ◽  
Estrogen Positive Feedback

scholarly journals Definition of Estrogen Receptor Pathway Critical for Estrogen Positive Feedback to Gonadotropin-Releasing Hormone Neurons and Fertility

Neuron ◽  
2006 ◽  
Vol 52 (2) ◽  
pp. 271-280 ◽  
Author(s):  
Tim M. Wintermantel ◽  
Rebecca E. Campbell ◽  
Robert Porteous ◽  
Dagmar Bock ◽  
Hermann-Josef Gröne ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Positive Feedback ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Estrogen Receptor Pathway ◽  
Definition Of ◽  
Estrogen Positive Feedback

scholarly journals Classical Estrogen Receptor α Signaling Mediates Negative and Positive Feedback on Gonadotropin-Releasing Hormone Neuron Firing

Endocrinology ◽  
2008 ◽  
Vol 149 (11) ◽  
pp. 5328-5334 ◽  
Author(s):  
Catherine A. Christian ◽  
Christine Glidewell-Kenney ◽  
J. Larry Jameson ◽  
Suzanne M. Moenter
Keyword(s):  
Estrogen Receptor ◽  
Positive Feedback ◽  
Estrogen Receptor Α ◽  
Gonadotropin Releasing Hormone ◽  
Neuron Firing ◽  
Releasing Hormone

scholarly journals Ligand-Independent Effects of Estrogen Receptor β on Mouse Gonadotropin-Releasing Hormone Promoter Activity

Endocrinology ◽  
2006 ◽  
Vol 147 (4) ◽  
pp. 1924-1931 ◽  
Author(s):  
Toni R. Pak ◽  
Wilson C. J. Chung ◽  
James L. Roberts ◽  
Robert J. Handa
Keyword(s):  
Estrogen Receptor ◽  
Promoter Activity ◽  
Gonadotropin Releasing Hormone ◽  
Estrogen Receptor Β ◽  
Releasing Hormone ◽  
Independent Effects

Gonadotropin releasing hormone (GnRH) reduces ligand-induced estrogen receptor (ER) dimerization in GT1-7 cells

2012 ◽  
Vol 98 (3) ◽  
pp. S202
Author(s):  
R.J. Chason ◽  
P.K. Leung ◽  
A.H. DeCherney ◽  
J.H. Segars ◽  
K.J. Catt
Keyword(s):  
Estrogen Receptor ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone

scholarly journals Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer

2012 ◽  
Vol 30 (5) ◽  
pp. 533-538 ◽  
Author(s):  
Pamela N. Munster ◽  
Amy P. Moore ◽  
Roohi Ismail-Khan ◽  
Charles E. Cox ◽  
Mensura Lacevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Ovarian Function ◽  
Estrogen Receptor Status ◽  
Gonadotropin Releasing Hormone ◽  
Control Group ◽  
Releasing Hormone ◽  
Neo Adjuvant Chemotherapy

Purpose Chemotherapy-induced amenorrhea is a serious concern for women undergoing cancer therapy. This prospective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserve ovarian function in women treated with chemotherapy for early-stage breast cancer. Patients and Methods Premenopausal women age 44 years or younger were randomly assigned to receive either triptorelin or no triptorelin during (neo)adjuvant chemotherapy and were further stratified by age (< 35, 35 to 39, > 39 years), estrogen receptor status, and chemotherapy regimen. Objectives included the resumption of menses and serial monitoring of follicle-stimulating hormone (FSH) and inhibin A and B levels. Results Targeted for 124 patients with a planned 5-year follow-up, the trial was stopped for futility after 49 patients were enrolled (median age, 39 years; range, 21 to 43 years); 47 patients were treated according to assigned groups with four cycles of adriamycin plus cyclophosphamide alone or followed by four cycles of paclitaxel or six cycles of fluorouracil, epirubicin, and cyclophosphamide. Menstruation resumed in 19 (90%) of 21 patients in the control group and in 23 (88%) of 26 in the triptorelin group (P= .36). Menses returned after a median of 5.8 months (range, 1 to 19 months) after completion of chemotherapy in the triptorelin versus 5.0 months (range, 0 to 28 months) in the control arm (P= .58). Two patients (age 26 and 35 years at random assignment) in the control group had spontaneous pregnancies with term deliveries. FSH and inhibin B levels correlated with menstrual status. Conclusion When stratified for age, estrogen receptor status, and treatment regimen, amenorrhea rates on triptorelin were comparable to those seen in the control group.

Sign in / Sign up

Export Citation Format

Share Document